Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer

Inclusion Criteria: * Male; Age ≥ 18 years. * Histological confirmation of adenocarcinoma of the prostate within 6 months of study enrollment. * Clinical stage T1-2 N0 M0, Gleason Score 7, Prostate Specific Antigen (PSA) 20-100 ng/mL, or Clinical stage Any T N0 M0, Gleason Score 8-10, PSA ≤ 100 ng/mL, or Clinical stage T3-4 N0 M0, any Gleason Score, PSA ≤ 100 ng/mL, or Clinical stage T1-2 N0 M0, Gleason Score 4+3, PSA 10-20 ng/mL * Zubrod performance score (PS) ≤ 1 * Total bilirubin, aspartate aminotransferase, alkaline phosphatase, and serum creatinine: \< 2 x upper normal limit * Signed informed consent. Exclusion Criteria: * Any known nodal (N1) or distant metastasis (M1) * Previous androgen deprivation therapy lasting more than 6 months * History of inflammatory bowel disease * Presence of a hip prosthesis * Prior pelvic radiotherapy or prostatectomy * Prior or concurrent antineoplastic agents (chemotherapy) * Previous or concurrent malignancy other than non-melanoma skin cancer within 5 years of diagnosis of prostate cancer. * Inability to start the protocol treatment within 1 month after study enrollment. * Medical or psychiatric conditions that preclude informed decision-making or compliance with the protocol treatment or follow-up